HIV Infection, HIV Infections
Conditions
Keywords
pharmacokinetics, single dose, raltegravir, Treatment experienced
Brief summary
The licensed dose of raltegravir is 400 mg twice daily with or without food. Raltegravir is metabolized predominantly through glucuronidation by UGT1A1. Atazanavir increases the plasma concentrations of raltegravir 400 mg twice daily by 72% due to inhibition of UGT 1A1. This suggests that combined use of atazanavir and a lower dose frequency of raltegravir, once daily for example, is possible. Another reason why raltegravir most likely can be applied is that its pharmacodynamic effect is not related to Cmin but to AUC which is expected to be similar for an 800mg QD dose when compared to 400mg BD. Phase III clinical trials evaluating QD dosing of raltegravir are currently ongoing and interim results are expected to be published in mid 2009. A regimen of atazanavir and raltegravir in combination with lamivudine or emtricitabine may be a well tolerated and effective NNRTI-, and ritonavir-sparing regimen that could be an attractive option for both first and second line (after NRTI/NNRTI failure) treatment regimens.
Interventions
DRUGraltegravir QD
Raltegravir 800mg QD
DRUGatazanavir
atazanavir
DRUGlamivudine (or emtricitabine)
lamivudine (or emtricitabine)
Sponsors
Radboud University Medical Center
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* HIV-infected as documented by positive HIV antibody test and confirmed by Western Blot. * Subject is at least 18 years of age at the day of screening. * Subject is able and willing to sign the Informed Consent Form prior to screening evaluations. * HIV-1 RNA \< 40 copies/mL for at least 6 months on antiretroviral therapy. * Subject has no history of previous virological failure or documented resistance mutations
Exclusion criteria
* History of sensitivity/idiosyncrasy to the drug or chemically related compounds or excipients, which may be employed in the trial. * Relevant history or current condition that might interfere with drug absorption, distribution, metabolism or excretion. * Inability to understand the nature and extent of the trial and the procedures required. * Pregnant female (as confirmed by an HCG test performed less than 3 weeks before the first dose) or breast-feeding female. * Abnormal serum transaminases determined as levels being \> 5 times upper limit of normal (see Appendix A for normal ranges of clinical laboratory values). * Concomitant use of medications that interfere with raltegravir or atazanavir pharmacokinetics: rifampicin, irinotecan, midazolam, triazolam, ergotamine, dihydroergotamine, cisapride, pimozide, lovastatin, simvastatin, indinavir, proton pump inhibitors, H2 receptor antagonists, St. john's wort, Ginkgo Biloba, didanosine, tenofovir, efavirenz, nevirapine, antacids, clarithromycin, phenytoin, phenobarbital, carbamazepine. * Active hepatobiliary or hepatic disease (including chronic hepatitis B infection). * Alcohol abuse.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| pharmacokinetics of raltegravir | after two weeks of reference treatment and after two weeks of test treatment |
Secondary
| Measure | Time frame |
|---|---|
| Viral load | after two weeks treatment with the reference treatment and after two weeks treatment with the test treatment |
| Adverse events | entire trial |
Countries
Germany, Netherlands
Outcome results
None listed